Drug recall · August 3, 2022
Insulin Glargine recall
Why: Labeling: Missing label: Label missing from some prefilled pens.
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens (NDC 49502-394-71), packaged in cartons of 5 prefilled pens (NDC 49502-394-75), Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 15317, Manufactured for: Mylan Specialty L.P., Morgantown, WV
- Lots / codes
Lot #: BF21002895, Exp. Date Aug 2023
- Quantity
- 253,200 pens (50,650/5 per packs)
- Company
- Mylan Pharmaceuticals Inc, Morgantown, WV
- Distribution
- Product was distributed nationwide within the United States
- Initiated
- July 5, 2022 · Voluntary: Firm initiated
- Classified
- July 26, 2022
- Reported
- August 3, 2022
- Ended
- February 26, 2024
- How notified
- Press Release
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Insulin glargine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.